BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37724378)

  • 1. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
    Shinkai M; Yabuta T
    Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
    Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
    Kurihara M; Kabata H; Irie M; Fukunaga K
    Allergol Int; 2023 Jan; 72(1):24-30. PubMed ID: 36470789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positioning of Tezepelumab in Severe Asthma.
    Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
    J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
    Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
    Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
    [No Abstract]   [Full Text] [Related]  

  • 7. Tezepelumab for asthma.
    Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
    Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R; Lugogo N; Corren J; Ambrose CS
    J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma.
    Cheng DT; Ma C; Niewoehner J; Dahl M; Tsai A; Zhang J; Gonsiorek W; Apparsundaram S; Pashine A; Ravindran P; Jung J; Hang J; Allard J; Bitter H; Tribouley C; Narula S; Wilson S; Fuentes ME
    J Allergy Clin Immunol; 2013 Aug; 132(2):455-62. PubMed ID: 23810153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TSLP in Asthma.
    Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
    J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
    Gauvreau GM; Sehmi R; Ambrose CS; Griffiths JM
    Expert Opin Ther Targets; 2020 Aug; 24(8):777-792. PubMed ID: 32567399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.
    Lin SC; Cheng FY; Liu JJ; Ye YL
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
    Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
    Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
    Nakajima S; Kabata H; Kabashima K; Asano K
    Allergol Int; 2020 Apr; 69(2):197-203. PubMed ID: 31974038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tezepelumab in patients with allergic and eosinophilic asthma.
    Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
    Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
    Rogliani P; Manzetti GM; Bettin FR; D'Auria M; Calzetta L
    Expert Opin Investig Drugs; 2024 Jan; 33(1):39-49. PubMed ID: 38206116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
    Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
    Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
    Salvati L; Maggi L; Annunziato F; Cosmi L
    Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.